글로벌 종양학 정보 시스템 시장 산업 개요 및 2031년까지의 예측 – 시장 분석 및 시장 규모

글로벌 종양학 정보 시스템 시장 - 산업 개요

글로벌 종양학 정보 시스템 시장은 암 발병률 증가, 기술 발전, 종양학 치료의 임상적 및 운영적 효율성을 향상시키는 통합 솔루션에 대한 필요성 증가로 인해 빠르게 확장되고 있습니다. 미국 국립 암 연구소(NCI)에 따르면 암은 전 세계적으로 사망의 주요 원인으로 남아 있으며, 2022년에는 약 2,000만 건의 신규 사례와 970만 건의 암 관련 사망이 보고되었습니다. OIS는 전자 건강 기록(EHR), 방사선 치료 계획, 화학 요법 관리를 포함하여 암 치료의 다양한 측면을 관리하도록 설계된 다양한 소프트웨어 도구를 포함합니다 . 시장의 성장은 암 발병률 증가와 고급 데이터 관리 및 분석이 필요한 개인화된 치료 접근 방식에 대한 수요에 의해 촉진됩니다.

Data Bridge Market Research Market Report는 최근의 새로운 개발 사항, 시장 점유율, 세분화 및 지역 분석에 따른 시장 동향, 시장 참여자의 영향, 새로운 수익 창출처 측면에서의 기회 분석, 시장 규정의 변화, 전략적 시장 성장 분석, 시장 규모, 범주 시장 성장, 응용 분야 틈새 시장 및 지배력, 제품 승인, 제품 출시, 지리적 확장, 시장의 기술 혁신에 대한 세부 정보를 제공합니다. 시장에 대한 자세한 정보를 얻으려면 Data Bridge Market Research의 전문가 분석가 팀에 문의하십시오. 저희 팀은 귀하가 사업 성장을 달성하기 위해 정보에 입각한 시장 결정을 내리는 데 도움을 드릴 것입니다.

글로벌 종양학 정보 시스템 시장 규모

Technological advancements, including cloud-based solutions and artificial intelligence, are significantly advancing the market by providing more accurate diagnostics and optimizing workflows. Furthermore, the use of machine learning algorithms enhances the prediction of patient outcomes and the customization of treatment plans, ultimately improving the overall quality of oncology care. As a result Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Oncology Information Systems Market is increasing at a CAGR of 7.90%. Our detailed analysis forecasts that the market is valued at USD 4.30 billion in 2023 and is expected to grow upto USD 7.91 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Oncology Information Systems Market Dynamics

Global Oncology Information Systems Market Growth Drivers

Increasing Prevalence of Cancer

According to National Cancer Institute by 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million.  As healthcare systems seek to manage the burgeoning volume of cancer patients and improve treatment outcomes, OIS technologies will play a crucial role in enhancing diagnostic precision, streamlining clinical workflows, and supporting personalized care approaches, thereby driving the global oncology information systems market.

Antibiotic Resistance

According to Personalized Medicine Coalition in 2020, personalized medicines accounted for 39 percent of newly approved Neuromuscular Electrical Stimulation (NMEs). The shift towards personalized medicine requires sophisticated data management and analysis tools. OIS systems are essential for tailoring treatment plans to individual patient profiles, thereby driving Global Oncology Information Systems Market growth.

Global Oncology Information Systems Market growth Opportunities

Demand for Streamlining Patient Information

The integration of oncology information systems (OIS) with existing electronic health record (EHR) systems presents Enhanced interoperability between OIS and EHRs which can streamline data management, leading to more efficient workflows and improved patient care. This integration facilitates seamless data exchange and better coordination across healthcare platforms thus fueling Global Oncology Information Systems Market growth.

Government and healthcare initiatives

Government investment in healthcare provides a huge potential opportunity for the global oncology information systems (OIS) market. For instance, the United States government has earmarked around $11.6 billion in 2023 for healthcare IT infrastructure under the "21st Century Cures Act," which intends to improve data interoperability and promote healthcare technologies. Such investments encourage the use and development of OIS solutions. Consequently fostering the Global Oncology Information Systems Market growth.

Global Oncology Information Systems Market growth Challenges

Complexity of System Integration

The System Integration process often requires extensive customization to align OIS with various data sources, electronic health records (EHRs), and other healthcare systems. This integration can disrupt clinical workflows and create operational challenges, as healthcare providers may face difficulties in synchronizing data, managing system compatibility, and ensuring smooth transitions from legacy systems to new technologies. Thus hindering the overall Global Oncology Information Systems Market growth.

Data Security and Privacy Concerns

Protecting sensitive patient information from unauthorized access and breaches is critical due to the increasing number of electronic health records and treatment data. Compliance with various rules, such as Australia's Privacy Act 1988, places rigorous restrictions on how personal data is handled and secured, whereas Canada's Personal Information Protection and Electronic Documents Act (PIPEDA) requires safeguards for personal health information. The high expenses of adopting and maintaining these security measures can be a significant barrier to OIS adoption. As a result, hampering the Global Oncology Information Systems Market growth.

Global Oncology Information Systems Market Restraints

Regulatory and market approval hurdles

The complexity of meeting various regulatory standards causes delays in the approval and deployment of OIS solutions, limiting market entrance and acceptance. For instance, in the European Union, OIS vendors must follow the Medical Device Regulation (MDR), that imposes severe standards for clinical studies and post-market supervision. The regulation necessitates comprehensive paperwork and rigorous testing, which extend the approval process and raise expenses.

Global Oncology Information Systems Market Scope and Trends

• The U.S. Department of Health and Human Services (HHS), via the Office of the National Coordinator for Health Information Technology (ONC), has released the Health Data, Technology, and Interoperability (HTI-2) proposed rule. This initiative underscores ONC’s commitment to enhancing interoperability and improving information exchange among patients, healthcare providers, insurers, and public health agencies.
• New TPS platforms use artificial intelligence and machine learning algorithms to enhance treatment planning and improve dosage administration accuracy. For instance, Varian's ARIA® oncology information system includes AI-powered tools such as SmartSegmentation, which uses machine learning to automate the segmentation of tumors and surrounding tissues, improving radiation therapy planning precision and reducing the time required for manual contouring.
• Surgical oncologists from Chennai's Apollo Cancer Centre (ACC) performed India's first Robotic Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal surface cancer. The minimally invasive, robotic-assisted method represents a paradigm shift in the treatment of Pseudomyxoma Peritonei (PMP), an aggressive appendix cancer, providing patients with a new standard of care which enables for faster recovery and better quality of life.
• Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) are becoming more advanced, allowing for highly targeted radiation delivery to tumors while minimizing damage to surrounding healthy tissues.
• C-Care and Healthcare Global Enterprises (HCG) partnered to provide cancer care services in Mauritius. HCG will offer clinical and outpatient consultation (OPD) services at the C-Care Cancer Center, which is housed within C-Care Darné in Floréal.

Global Oncology Information Systems Market Regional Analysis – Market Trends

Key Insights

• The North American market dominates the global Oncology Information Systems (OIS) market driven by high adoption of cutting-edge technologies, and the presence of major industry players. The U.S. leads the region, benefiting from substantial investments in cancer research and the increasing integration of AI in healthcare.
• 아시아 태평양 지역은 의료비 지출 증가, 암 발병률 증가, 디지털 건강에 대한 정부 지원으로 인해 OIS 시장에서 빠른 성장을 경험하고 있습니다. 중국과 인도와 같은 국가는 OIS 인프라에 대한 상당한 투자를 목격하고 있습니다.
• 유럽 ​​OIS 시장은 의료비 지출 증가, 전자 건강 기록(EHR)에 대한 정부 규제, 암 치료 개선에 있어 OIS의 이점에 대한 인식 증가 등의 요인에 힘입어 꾸준한 성장을 경험하고 있습니다.

글로벌 종양학 정보 시스템 시장 선도 기업

• Koninklijke Philips NV(네덜란드)
• Varian Medical Systems, Inc(영국)
• 맥케슨 코퍼레이션(미국)
• 지멘스(독일)
• 엘렉타(스웨덴)
• 에픽 시스템즈 코퍼레이션(미국)
• IBM(미국)
• Cerner Corporation (미국)
• 고급 데이터 시스템(미국)
• BMSI 파트너스 주식회사(미국)
• F. Hoffmann-La Roche AG(스위스)
• AmerisourceBergen Corporation(미국)
• 제너럴 일렉트릭(미국)
• Accuray Incorporated (미국)
• OPTUM Inc.(미국)
• Allscripts Healthcare Solutions, Inc. (미국)
• MICA 정보 시스템 주식회사(미국)
• CureMD Healthcare(미국)
• 엔도소프트 LLC(미국)
• RaySearch Laboratories(스웨덴)

글로벌 종양학 정보 시스템 시장 최근 개발

• 2024년 5월 RaySearch Laboratories AB는 자사의 종양학 정보 시스템인 RayCare* 2024A가 Varian TrueBeam 선형 가속기 버전 3.0과의 호환성을 인증받았다고 발표했습니다. RaySearch와 Varian Medical Systems는 2024년 내내 테스트 활동에 협력하여 이 인증을 받았습니다.
• 2024년 4월, 스톡홀름 - GE HealthCare가 인수한 의료 영상 관리 및 인공지능 솔루션 분야의 선도적 공급업체인 Elekta와 MIM Software Inc는 방사선 치료 제공에서 고급 치료 계획을 위한 동급 최고의 솔루션을 결합하기 위한 협업을 발표했습니다.
• 2024년 5월 스톡홀름 - Elekta는 최신 선형 가속기(linac)인 Evo*를 출시한다고 발표했습니다. Evo*는 새로운 고화질 AI 강화 이미징을 탑재한 CT-Linac으로 오프라인 및 온라인 적응형 방사선 치료와 더 나은 기존 영상 유도 방사선 치료를 제공할 수 있습니다. 이 고도로 적응 가능한 CT-Linac을 사용하면 임상의가 각 환자에게 가장 적합한 방사선 치료 기술을 선택할 수 있습니다.

SKU-56104